Urogen Pharma (NASDAQ:URGN) Price Target Raised to $75.00 at HC Wainwright

Urogen Pharma (NASDAQ:URGN) had its target price hoisted by analysts at HC Wainwright from $45.00 to $75.00 in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 61.53% from the company’s previous close.

Several other equities research analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. LADENBURG THALM/SH SH assumed coverage on shares of Urogen Pharma in a research note on Monday, May 11th. They set a “buy” rating and a $43.00 target price on the stock. Oppenheimer raised their target price on Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. Finally, Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $47.00.

Urogen Pharma Trading Up 16.3%

NASDAQ URGN opened at $46.43 on Thursday. The firm has a market capitalization of $2.26 billion, a PE ratio of -16.88 and a beta of 1.57. The business’s 50-day moving average price is $35.73 and its two-hundred day moving average price is $26.80. Urogen Pharma has a 12 month low of $15.86 and a 12 month high of $47.84.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to the consensus estimate of $63.55 million. As a group, analysts forecast that Urogen Pharma will post -0.76 earnings per share for the current fiscal year.

Insider Transactions at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider owned 119,763 shares in the company, valued at $4,790,520. This represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,222 shares of company stock worth $892,661. 4.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Urogen Pharma

Several institutional investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP purchased a new stake in shares of Urogen Pharma during the 3rd quarter valued at $84,111,000. Soleus Capital Management L.P. purchased a new stake in Urogen Pharma during the second quarter worth about $29,934,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Urogen Pharma in the fourth quarter worth about $26,350,000. MPM Bioimpact LLC boosted its stake in Urogen Pharma by 597.3% in the fourth quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock valued at $22,047,000 after acquiring an additional 806,378 shares during the last quarter. Finally, TCG Crossover Management LLC bought a new position in shares of Urogen Pharma during the 3rd quarter valued at approximately $14,311,000. 91.29% of the stock is owned by institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.